Oxford Biomedica Solutions
Rudenc (Deni) Lushi is a Scientist I in Analytical Development at Oxford Biomedica since January 2023, focusing on Analytical Ultracentrifugation methods and AAV-specific HPLC assays. Prior roles include Sr. Research Associate II at Oxford Biomedica Solutions and Homology Medicines, Inc., where significant experience in analytical development was gained. Deni has also served as the Head Coach for the Boston University Women's Club Volleyball team, demonstrating strong leadership and organizational skills. Earlier experience includes a position as a Research and Development Engineer at Agira Photonics, contributing to innovative optical designs and product development. Deni holds a Bachelor of Arts degree in Neurobiology and Biomedical Engineering from Boston University.
This person is not in the org chart
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.